开发强大的SHP2菌抑制剂:设计,合成和评估与抗瘤效应
Cheng Shi1, Yanping Zhao1,2, Han Huang1
1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Journal of medicinal chemistry
|March 4, 2025
概括
使用碎片拼接开发了新的SHP2抑制剂. 化合物B8显示出强大的抑制和抗瘤活性,为向SHP2 (Src同质-2-含蛋白质氨酸酸酶2) 的癌症治疗开发提供了有希望的头.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 含有Src同质-2-蛋白质氨酸酸酶2 (SHP2) 对于细胞信号传递至关重要.
- 过度表达SHP2与各种癌症有关,需要针对性治疗.
研究的目的:
- 设计和合成新的全性SHP2抑制剂.
- 评估新化学实体的抑制潜力和抗瘤活性.
主要方法:
- 活性碎片拼接方法用于抑制剂设计.
- 提亚[5,4-b]二烯和伊米达[1,2-c]二烯衍生物的合成.
- 在体外酶抑制试验和体内异种移植研究.
主要成果:
- 新的衍生品显示出强大的SHP2抑制 (IC50:9.0-34.5nM).
- 化合物B8表现出显著的强度和调节的p-ERK信号 (IC50:0.04μM).
- 化合物B8在小鼠模型中显示出有利的类似药物的特性和抗瘤功效.
结论:
- 开发的化合物是有效的全性SHP2抑制剂.
- 化合物B8是SHP2向癌症治疗的有希望的主要候选者.
- 这项研究为推进SHP2向治疗提供了基础.
更多相关视频
06:56Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
279
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
